<div id="readability-page-1"><h3>Claim 30% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Collplant Holdings ( (CLGN) ) has shared an update. On March 23, 2026, CollPlant Biotechnologies received a Nasdaq notice that its ordinary shares had closed below $1.00 for 30 consecutive business days, putting the company out of compliance with Nasdaq Listing Rule 5550(a)(2). Under Nasdaq rules, CollPlant has until September 21, 2026 to restore its bid price to at least $1.00 for 10 consecutive business days, during which time its shares will continue trading on the Nasdaq Capital Market. If CollPlant fails to regain compliance by September 21, 2026, it may qualify for a second 180-day grace period provided it meets other listing standards and commits to curing the deficiency, potentially via a reverse share split. The notification heightens delisting risk and underscores continued share-price pressure, but the extended timeline gives management room to consider remedial actions while maintaining the stock’s current Nasdaq listing in the near term. The most recent analyst rating on (CLGN) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page. Spark’s Take on CLGN Stock According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral. The score is held down primarily by weak financial performance—large ongoing losses, heavy cash burn, and a shrinking equity base despite some TTM revenue and gross margin improvement. Technicals provide partial support with a stronger short-term trend, but longer-term trend and momentum are mixed. Valuation remains unattractive due to negative earnings and no dividend yield. To see Spark’s full report on CLGN stock, click here. More about Collplant Holdings CollPlant Biotechnologies Ltd. is an Israel-based regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on proprietary recombinant human collagen (rhCollagen) produced via plant-based genetic engineering, targeting tissue repair, aesthetics and organ manufacturing, and include a dermal and soft tissue filler collaboration with Allergan, an AbbVie company. Average Trading Volume: 80,540 Technical Sentiment Signal: Sell Current Market Cap: $8.74M For an in-depth examination of CLGN stock, go to TipRanks’ Overview page.</div>

CLGN

LABU

IBBQ

CollPlant Biotechnologies has received a Nasdaq notice for non-compliance due to its shares closing below $1.00 for 30 consecutive business days. The company has until September 21, 2026, to restore compliance or may face delisting. Analysts rate CLGN stock as a Sell with a $2.00 price target, citing weak financial performance and ongoing losses. CollPlant focuses on regenerative medicine and 3D bioprinting, with a current market cap of $8.74M.

Tip Ranks

Invesco Biotechnology & Genome ETF

CollPlant Biotech

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

CollPlant Biotechnologies Faces Nasdaq Bid-Price Deficiency, Granted Compliance Window